MAP2 and myalgic encephalomeyelitis/chronic fatigue syndrome: Various general autoantibodies have also been identified in ME/CFS, such as those against cellular components including anchorage molecules (514), HSP-60 (515), microtubule associated protein 2 (516), cardiolipin in 92-95% of ME/CFS patients in two studies (509, 510) but only 4% in another study (506), and neo-antigens (517).